Ordering from the Americas?Switch to the US store
We don't ship to your country yet. We ship across Europe and the Americas. You can keep browsing.

Peptency Academy · Guide

Regulatory status of peptide patches in the US, EU and UK

How are peptide patches classified and regulated in the US, the EU and the UK?

A 2025 white paper expects a microneedle and active substance sold as one unit to be classed as a combination or medicinal product, and calls the regulatory science for this product form immature, with limited explicit guidance. Source sentenceAbstract, first sentences: regulatory science for this emerging product form is immature and explicit guidance is limited.1 J Control Release 2025

Version 1Edited 6 sources

Regulatory content shown for: EU and UK.

Known, not known, contested

Known

  • The same paper identifies more than twenty critical quality attributes for the product form and ranks which of them need bespoke tests. Source sentenceAbstract, final sentences: a prioritisation exercise identifies the most pertinent attributes.1 J Control Release 2025

Not known

Contested

Nothing listed yet.

European Union: the EMA guideline and cosmetics law

EU

  • The EMA guideline on quality of transdermal patches applies to patches for systemic delivery. Cutaneous patches not meant for systemic absorption are out of its scope. Source sentenceCutaneous patches (where the active substance is not intended to be systemically absorbed) are out of the scope of this guideline.3 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  • EU cosmetics law defines a cosmetic product by contact with external body parts and a purpose of cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting body odour. Source sentence‘cosmetic product’ means any substance or mixture intended to be placed in contact with the external parts of the human body ... with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours4 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk
  • A substance intended to enter the body, for example by ingestion or implant, is not a cosmetic product under the same article. Source sentencea substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product4 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk

United Kingdom: the borderline between cosmetic and medicine

UK

  • In Great Britain a product that fits both the cosmetic definition and the medicinal definition is classified as a medicinal product. (reported by MHRA, read through a search summary) Source sentenceMHRA guidance: a product that falls within both the cosmetic and the medicinal product definition is classified as a medicinal product.5 MHRA, borderline products guidance for Great Britain

European Union: the guideline in force

EU

How are peptide patches classified under EU and UK rules?

In the EU, patches for systemic delivery fall under the EMA quality guideline. A product placed on external body parts mainly to clean, perfume, change appearance, protect or keep them in condition is a cosmetic, unless it is meant to enter the body. Source sentenceThis guideline addresses new marketing authorisation applications ... for transdermal patches for systemic delivery.3 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/20144 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk In Great Britain the medicinal definition wins where a product also fits the cosmetic one. (reported by MHRA, read through a search summary) Source sentenceMHRA guidance: both definitions apply, so the product is classified as a medicinal product.5 MHRA, borderline products guidance for Great Britain

Published examples with IDs

  1. Analytical only (no biological model)Journal of controlled release : official journal of the Controlled Release Society 2025

    Classification, nomenclature and more than twenty critical quality attributes

    Design
    White paper by international stakeholders on regulatory science of microneedle product forms
    Molecule
    Microneedle product forms not established

    PubMed 39603537DOI

  2. Analytical only (no biological model)The Annals of pharmacotherapy 2026

    Count of patch products, listed ingredients and posted certificates of analysis

    Design
    Review of patch dietary supplement products sold as natural GLP-1 products
    Molecule
    Supplement patch products not established
    n
    25

    PubMed 41480958DOI

Sources

  1. 1J Control Release 2025 accessed 11 Nov 2026
  2. 2PubMed search for transdermal patch without microneedles, 11 November 2026 accessed 11 Nov 2026
  3. 3EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 accessed 11 Nov 2026
  4. 4Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk accessed 11 Nov 2026
  5. 5MHRA, borderline products guidance for Great Britain accessed 11 Nov 2026
  6. 6Ann Pharmacother 2026 accessed 11 Nov 2026

About this page

Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.

Reviewed by the Peptency editorial process. Version 1, edited 11 November 2026, 6 sources.

Cite this page: Peptency Academy. Regulatory status of peptide patches in the US, EU and UK. Version 1./eu/academy/guides/peptide-patch-regulatory-status-us-eu-uk/